Key result
Tobacco use is linked to ~97% higher odds of dyslipidemia during isotretinoin therapy.
Why the study?
Oral isotretinoin for severe acne vulgaris is associated with dyslipidemia, and this study sought to investigate its incidence and predictors as well as the impact of dose reduction on lipid panels.
What are the incidence and risk factors for developing dyslipidemia in patients with severe acne vulgaris treated with oral isotretinoin, and does a 50% dose reduction improve lipid parameters?
Observational (n=498)
No
What are the incidence and risk factors for developing dyslipidemia in patients with severe acne vulgaris treated with oral isotretinoin, and does a 50% dose reduction improve lipid parameters?
In young adults receiving oral isotretinoin for severe acne with normal baseline lipids, 11.4% developed dyslipidemia (predominantly around 3 months, with smoking nearly doubling the risk), and a 50% dose reduction significantly reduced elevated triglyceride levels without requiring drug discontinuation.
Answers are grounded in this paper and cite their sources.
Lipid monitoring may be prudent for smokers on isotretinoin; leaves open whether targeted strategies improve outcomes in prospective trials.
Background and Objectives: Oral isotretinoin has revolutionized the treatment of severe acne vulgaris. Isotretinoin is associated with multiple adverse effects, one of which is dyslipidemia (DLP). Materials and Methods: This single-center prospective study recruited 498 patients who were eligible for isotretinoin for severe acne. Risk factors for hyperlipidemia and serum lipids were assessed at baseline. Patients received daily doses ranging from 0.25 to 1 mg/kg of their body weight, and their fasting serum lipids were checked regularly until they reached a cumulative dose of 120–150 mg/kg. Our primary objective is to investigate dyslipidemia incidence and predictors, while the secondary objective is to assess the impact of dose reduction on lipid panels. Results: Our sample was primarily female (n = 380, 76.3%), with a normal Body Mass Index (23.2 ± 4.0) and a mean age of 20.7 (±4.1) years. About 72.5% had a family history of acne, 17.1% a family history of dyslipidemia. Around 17.3% reported tobacco use. A total of 57 (11.4%) patients on isotretinoin developed DLP. Smoking was independently associated with a higher risk of dyslipidemia (OR 1.97, 95% CI [1.01, 3.82], p = 0.046). The mean onset of DLP was at 3.23 (±2.13) months. A total of 52 patients out of the 57 had a dose reduction of 10 mg (n = 5) or 20 mg (n = 47). A dose reduction of 50% was found to significantly improve triglyceride levels. Conclusions: More than 1 out of 10 patients on isotretinoin developed DLP. Tobacco use was significantly associated with developing DLP. Dose reduction significantly impacted a decrease in triglyceride levels.
No takes yet. Share an insight, caveat, or question.
Muhaidat et al. (2025) conducted an observational in Severe acne vulgaris (n=498). Systemic isotretinoin (and tobacco use as a primary predictor) vs. Non-smokers / baseline pre-treatment was evaluated on Incidence of dyslipidemia (HDL <1.04 mmol/L in males or <1.29 mmol/L in females, LDL >4.12 mmol/L, triglycerides >2.26 mmol/L, or total cholesterol >6.19 mmol/L) and association with tobacco use (OR 1.97, 95% CI 1.01, 3.82, p=0.046). Systemic isotretinoin therapy led to dyslipidemia in 11.4% of severe acne patients, with tobacco use independently increasing dyslipidemia risk.
Synapse has enriched 10 related papers. Consider them for comparative context: